Cargando…
Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363299/ https://www.ncbi.nlm.nih.gov/pubmed/35851443 http://dx.doi.org/10.1007/s40273-022-01170-6 |
| _version_ | 1784764899967107072 |
|---|---|
| author | Gandjour, Afschin |
| author_facet | Gandjour, Afschin |
| author_sort | Gandjour, Afschin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9363299 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93632992022-08-11 Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective” Gandjour, Afschin Pharmacoeconomics Letter to the Editor Springer International Publishing 2022-07-19 2022 /pmc/articles/PMC9363299/ /pubmed/35851443 http://dx.doi.org/10.1007/s40273-022-01170-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Letter to the Editor Gandjour, Afschin Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective” |
| title | Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective” |
| title_full | Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective” |
| title_fullStr | Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective” |
| title_full_unstemmed | Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective” |
| title_short | Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective” |
| title_sort | comment on “cost effectiveness of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening heart failure event from a us medicare perspective” |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9363299/ https://www.ncbi.nlm.nih.gov/pubmed/35851443 http://dx.doi.org/10.1007/s40273-022-01170-6 |
| work_keys_str_mv | AT gandjourafschin commentoncosteffectivenessofvericiguatforthetreatmentofchronicheartfailurewithreducedejectionfractionfollowingaworseningheartfailureeventfromausmedicareperspective |